Literature DB >> 12190329

Context-sensitive half-times: what are they and how valuable are they in anaesthesiology?

James M Bailey1.   

Abstract

The context-sensitive half-time is the time required for blood or plasma concentrations of a drug to decrease by 50% after discontinuation of drug administration. The context-sensitive half-time often cannot be predicted by the elimination half-life (a measure of the time needed for actual drug metabolism or elimination) since it also depends on drug distribution. The context-sensitive half-time is a function of the duration of drug administration and may only be estimated by computer simulation. It is more relevant than other isolated pharmacokinetic parameters to understanding the kinetics of drug concentrations. However, understanding the kinetics of drug effect requires concomitant consideration of pharmacodynamics.

Mesh:

Substances:

Year:  2002        PMID: 12190329     DOI: 10.2165/00003088-200241110-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  20 in total

1.  A dynamic concept of the distribution of thiopental in the human body.

Authors:  H L PRICE
Journal:  Anesthesiology       Date:  1960 Jan-Feb       Impact factor: 7.892

2.  Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs.

Authors:  M A Hughes; P S Glass; J R Jacobs
Journal:  Anesthesiology       Date:  1992-03       Impact factor: 7.892

3.  Context-sensitive half-times and other decrement times of inhaled anesthetics.

Authors:  J M Bailey
Journal:  Anesth Analg       Date:  1997-09       Impact factor: 5.108

4.  Pharmacokinetic parameters relevant to recovery from opioids.

Authors:  E J Youngs; S L Shafer
Journal:  Anesthesiology       Date:  1994-10       Impact factor: 7.892

5.  Pharmacodynamics of propofol in female patients.

Authors:  J Vuyk; F H Engbers; H J Lemmens; A G Burm; A A Vletter; M P Gladines; J G Bovill
Journal:  Anesthesiology       Date:  1992-07       Impact factor: 7.892

6.  Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers.

Authors:  H Ericsson; U Bredberg; U Eriksson; A Jolin-Mellgård; M Nordlander; C G Regårdh
Journal:  Anesthesiology       Date:  2000-04       Impact factor: 7.892

7.  Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group.

Authors:  J M Bailey; C T Mora; S L Shafer
Journal:  Anesthesiology       Date:  1996-06       Impact factor: 7.892

8.  Concentrations of desflurane and propofol that suppress response to command in humans.

Authors:  B S Chortkoff; E I Eger; D P Crankshaw; C T Gonsowski; R C Dutton; P Ionescu
Journal:  Anesth Analg       Date:  1995-10       Impact factor: 5.108

9.  The pharmacodynamic interaction of propofol and alfentanil during lower abdominal surgery in women.

Authors:  J Vuyk; T Lim; F H Engbers; A G Burm; A A Vletter; J G Bovill
Journal:  Anesthesiology       Date:  1995-07       Impact factor: 7.892

10.  Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers.

Authors:  T D Egan; C F Minto; D J Hermann; J Barr; K T Muir; S L Shafer
Journal:  Anesthesiology       Date:  1996-04       Impact factor: 7.892

View more
  10 in total

1.  Time of effect duration and administration interval for sitagliptin in patients with kidney failure.

Authors:  Frieder Keller; Bertram Hartmann; David Czock
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-12-19       Impact factor: 2.441

2.  Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.

Authors:  Sandeep Dutta; Ronald C Reed
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 3.  Pharmacokinetic/pharmacodynamic modeling of anesthetics in children: therapeutic implications.

Authors:  Jean-Xavier Mazoit
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 4.  Remifentanil update: clinical science and utility.

Authors:  Richard Beers; Enrico Camporesi
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  First administration to man of Org 25435, an intravenous anaesthetic: A Phase 1 Clinical Trial.

Authors:  Ann E Rigby-Jones; J Robert Sneyd; Peter Vijn; Patrick Boen; Maurice Cross
Journal:  BMC Anesthesiol       Date:  2010-06-29       Impact factor: 2.217

6.  Assessing the utility of the utility function.

Authors:  Evan D Kharasch; Carl E Rosow
Journal:  Anesthesiology       Date:  2013-09       Impact factor: 7.892

7.  Increasing cumulative exposure to volatile anesthetic agents is associated with poorer neurodevelopmental outcomes in children with hypoplastic left heart syndrome.

Authors:  Laura K Diaz; J William Gaynor; Shannon J Koh; Richard F Ittenbach; Marsha Gerdes; Judy C Bernbaum; Elaine H Zackai; Robert R Clancy; Mohamed A Rehman; Jeffrey W Pennington; Nancy Burnham; Thomas L Spray; Susan C Nicolson
Journal:  J Thorac Cardiovasc Surg       Date:  2016-04-18       Impact factor: 5.209

Review 8.  Delayed arousal.

Authors:  Zirka H Anastasian; Eugene Ornstein; Eric J Heyer
Journal:  Anesthesiol Clin       Date:  2009-09

9.  The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms.

Authors:  Selma Sahin; Leslie Z Benet
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

10.  Comparison of Infusion of Propofol and Ketamine-Propofol Mixture (Ketofol) as Anesthetic Maintenance Agents on Blood Pressure of Patients Undergoing Orthopedic Leg Surgeries.

Authors:  Amir Sabertanha; Bibifatemeh Shakhsemampour; Mina Ekrami; Elahe Allahyari
Journal:  Anesth Pain Med       Date:  2019-11-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.